Atlas Trials

A Biomarker Study of Palbociclib + Fulvestrant for Second, and Third Line of Postmenopausal Women With hr+/her2- Advanced Breast Cancer

Clinical trial NCT03560856 · UNKNOWN

Trial details

NCT number
NCT03560856
Sponsor
Assistance Publique - Hôpitaux de Paris
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Breast CancerHR+/HER2-negative Breast CancerMetastasis
Start date
2018-06-27
Primary completion
2022-06-01
Enrollment
54

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.